- Home
- INAB
INAB
IN8bio Inc.
as 04-01-2025 3:37pm EST
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 18.8M | IPO Year: | 2021 |
| Target Price: | $3.60 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.16 - $1.74 | Next Earning Date: | 03-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest IN8bio Inc. News
INAB Breaking Stock News: Dive into INAB Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025
GlobeNewswire
14 days ago
IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025
Zacks Small Cap Research
15 days ago
INAB: Introducing INB-600, A γδ T Cell Engager Platform
MT Newswires
18 days ago
HC Wainwright Adjusts IN8bio Price Target to $6 From $8, Maintains Buy Rating
GlobeNewswire
19 days ago
IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
GlobeNewswire
a month ago
IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases
GlobeNewswire
a month ago
IN8bio to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewswire
a month ago
IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Compare INAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INAB IN8bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.